Research article

**Muscle Specific Fragile X Related Protein 1 Isoforms are Sequestered in the Nucleus of Undifferentiated Myoblast**

Marthe Dubé, Marc-Etienne Huot and Edouard W Khandjian

**Address:** Unité de Recherche en Génétique Humaine et Moléculaire, Hôpital Saint François d’Assise du CHUQ, Québec, (Qc) G1L 3L5 and Département de biologie médicale, Faculté de médecine, Université Laval, Québec, Canada.

E-mail: Marthe Dubé - miracle_marthe@hotmail.com Marc-Etienne Huot - squall_98@hotmail.com Edouard W Khandjian - edward.khandjian@crsfa.ulaval.ca

**Abstract**

**Background:** The family of Fragile X Mental Retardation Proteins is composed of three members: Fragile Mental Retardation 1, Fragile X Related 1 and X Related 2 proteins. These proteins are associated with mRNPs within translating ribosomes and have the capacity to shuttle between the nucleus and the cytoplasm. Great attention has been given to FMRP due to its implication in human hereditary mental retardation while FXR1P and FXR2P have only recently been studied.

**Results:** Using antibodies directed against several epitopes of FXR1P, we have detected protein isoforms generated by small peptides pocket inserts. Four isoforms of MW 70, 74, 78, 80 kDa are widely distributed in mouse organs, while in striated muscles these isoforms are replaced by proteins of 82 and 84 kDa containing an extra pocket of 27 aa. Expression of these muscle isoforms is an early event during *in vitro* differentiation of myoblasts into myotubes and correlates with the activation of muscle-specific genes. However, while FXR1P82,84 are associated with cytoplasmic mRNPs in myotubes, they are sequestered in the nuclei of undifferentiated myoblasts. These observations suggest that, in addition to a cytoplasmic function yet to be defined, FXR1P82,84 may play a nuclear role in pre-mRNA metabolism.

**Conclusions:** The pattern of subcellular partitioning of FXR1P isoforms during myogenesis is unique among the family of the FXR proteins. The model system described here should be considered as a powerful tool for ongoing attempts to unravel structure-function relationships of the different FMR family members since the potential role(s) of FXR1P as a compensatory factor in Fragile X syndrome is still elusive.

**Background**

The Fragile X Mental Retardation (FMR) protein family is composed of three highly homologous members. The Fragile X Mental Retardation Protein (FMRP) is coded by the X-linked *FMR1* gene and its absence is directly associated with human hereditary mental retardation [reviewed in 1,2]. Two other members of this family are the Fragile X Related 1 (FXR1P) and Fragile X Related 2 (FXR2P) proteins [3,4,5] that are coded by the *FXR1* and *FXR2* genes located at 3q28 and 17p13.1, respectively, in human. These genes are highly conserved in vertebrate evolution and contain two KH domains and a RGG box that are functional characteristic motifs in RNA-binding proteins [4,5,6,7]. In addition, they also contain a nuclear localization signal (NLS) as well as a nuclear export signal (NES) making them putative nucleocytoplasmic shuttling proteins [reviewed in 1,2]. Finally, FMRP as well as the other members of the family have been shown to be associated with messenger RibonucleoParticles
(mRNP) within actively translating ribosomes. This association suggests that their roles might be linked to RNA transport and/or translation [8,9,10,11,12].

Whereas absence of FMRP is the cause of Fragile X Mental Retardation in human, it is not known whether FXR1P and FXR2P are associated to any pathology or phenotype. Also it is not known whether these homologous proteins can compensate for the absence of FMRP in the case of the Fragile X syndrome. In vitro studies showed that all three members interact with themselves and with each other [5, 13, 14]. However, their distribution in certain mouse and human tissues showed individual pattern of expression [15, 16] indicating that each protein also may function autonomously [17].

FXR1P has been shown to have a complex expression pattern in different mammalian cell lines since six distinct isoforms were observed and their respective levels were shown to be cell type specific [12]. In particular, it was observed that 4 distinct FXR1P isoforms of MW 70 and 74 kDa (previously referred to as short) and 78 and 80 kDa (long) are widely expressed in diverse cell lines as well as in different organs in mouse. However, in muscle, these isoforms are replaced by novel super long isoforms of MW 82 and 84 kDa. The replacement of the short and long isoforms by the super long isoforms is clearly apparent during myogenesis of myoblastic cell lines that can differentiate in vitro into myotubes. This model system which mimics, although imperfectly, muscle differentiation has permitted us to show in the present report that transition of the short and long isoforms to the super long is an early event that takes place concomitantly to the expression of muscle-specific genes. In addition, we also show that low levels of the super long isoforms are constitutively expressed in undifferentiated myoblasts and that they are sequestered in the nuclei, while in differentiated myotubes P82,84 are transferred to the cytoplasm where they are incorporated in mRNPs present in actively translating ribosomes.

Results

Complex expression of FXR1P isoforms

Initial reports of FXR1 cloning described the presence of two mRNA variants [3,4] while recent analyses showed that at least 7 mRNA variants can be detected [18]. These alternatively spliced mRNA differ each from other by the presence or absence of four different exon sequences. A virtual representation of the corresponding deduced protein isoforms is shown in Figure 1. For the identification of the different proteins corresponding to the different mRNA variants (iso a to iso g) we used the numbering of Kirkpatrick et al. [18]. For convenience, the different proteins are illustrated in order of decreasing length. All of the seven FXR1P isoforms contain the same unmodified region from amino acids 1 to 379 after which the addition or lack of different small peptide pocket inserts are due to alternative spliced mRNA variants. Addition of 87, 78 and 81 nucleotides inserts in different mRNA directs the synthesis of 29, 26, and 27 extra amino acid pockets, (exon 12, 13 and 15 boxes in Figure 1b) respectively. A fourth spliced variant of 92 nucleotides induces a frameshift that results in the addition of 30 amino acids and a C-terminal with a final product of 677 amino acid long protein. When the 92 nucleotides sequence is absent, a stop codon at bases 1878-1880 of the mRNA allows the synthesis of only 5 additional amino acids and the C-terminal is thus truncated (Figure 1b).

We have previously described two antibodies, mAb3FX and rabbit polyclonal serum #830, that detect different FXR1P isoforms [12]. To obtain new antibodies to the muscle specific isoforms, two synthetic polypeptides corresponding to stretches in the 27 aa sequence present in the muscle super long FXR1P isoforms [12,18] were used.
to immunize rabbits. Two polyclonal sera #27-15 and #27-17 were obtained. The different regions that are recognized by the antibodies are shown in Figure 1b. In theory, mAb3FX should have reacted with the 7 isoforms, however because of the differences of 1 to 3 amino acids between iso c, iso f and iso g (650, 648 and 651 aa) it was not possible to resolve these proteins by SDS-PAGE. The specificity of the antibodies to the different FXR1P isoforms as well as the distribution of the different isoforms in several mouse tissues is shown in Figure 2. A complex distribution of the 70, 74, 78, and 80 kDa isoforms is observed using mAb3FX. In agreement with previous observations [12] none of these isoforms are detected in muscle and heart extracts. Instead, super long isoforms of 82 and 84 kDa are present in these tissues. These observations were clearly confirmed with the use of antiserum #830 which detects the 78, 80, 82 and 84 kDa isoforms and also with #27-15 and #27-17 sera that are specific to the 82 and 84 kDa isoforms. The additional band detected at 94 kDa with mAb3FX corresponds to the closely homologous Fragile X Related 2 protein [5] recognized by this monoclonal antibody since part of the peptide used for immunization is present in FXR2P.

To compare P82,84 in heart and muscle, protein extracts prepared from these tissues were subjected to two-dimension gel electrophoresis followed by immunoblot analyses using #27-15 antiserum. P82,84 appear to undergo major post-translational modifications and three variants with pI 6.0, 5.7 and 5.4 were detected for each protein in both tissues, however with slight different distributions. Additional minor forms were also detected around pI 6.6 (Figure 3). These results strongly suggest that in these two tissues P82,84 have identical distribution. Indeed, in situ immunostaining of FXR1P in longitudinal sections from adult mouse limb muscle and heart with #27-15 (or #27-17) showed punctuated immunoreactive sites associated mainly with the myocontractile structures (Figure 4). Identical staining patterns were obtained with mAb3FX and #830 as previously shown [12] since these antibodies also detect P82,84 while the other FXR1P isoforms are absent in these tissues. Similar if not identical pictures for mouse muscle were also reported recently [16] with the use of a different antibody (Ab2107). The distribution and specific punctuated features of P82,84 staining in striated muscles are reminiscent of that seen for costameres structures containing RNA and protein [19,20]. These structures lie between the cell membrane and the Z line in skeletal and cardiac muscles [21].

Accumulation of FXR1P82,84 isoforms during in vitro myogenesis

We have shown previously that the replacement of P70-
80 by P82,84 correlates with differentiation of C2C4 myoblasts into myotubes after serum removal [12]. This mouse myogenic cell line is derived from the original skeletal muscle cell line C2 and is considered permissive since it can readily differentiate in myotubes in medium containing low serum concentrations [22]. To establish more precisely the timing of the replacement of the short and long isoforms by the super long, proteins were prepared at different times after serum starvation and analyzed by immunoblotting. The kinetics of expression of the different FXR1P isoforms is presented in Figure 5. In non-differentiated myoblasts prominent bands were observed at 70, 74, 78 and 80 kDa as well as the 94 kDa FXR2P. As early as 24 h after induction, high levels of P82,84 were detected while levels of the other FXR1P isoforms started to decline. By three days after serum deprivation, P82,84 levels reached a maximum plateau and only faint bands corresponding to the other isoforms were detected. A better picture was obtained using antiserum #27-15 specific to the super long isoforms and unexpectedly allowed us to detect low levels of P82,84 in non-differentiated myoblasts. The results presented above clearly showed that increased accumulation of P82,84 has taken place during the first 24 h after serum starvation at a time when no morphological changes are detected at the microscopic level. To test for the hypothesis that the induction of P82,84 is an early event that is directly linked to the initial commitment of myoblasts to differentiate into myotubes, protein extracts were prepared at different times over a period of 24 h after serum depletion. Immunoblot analyses showed that trace amounts of P82,84 were present in undifferentiated myoblasts. Increasing levels of P82,84 were detected as early as 12-15 h (Figure 6 upper panels). At this time, accumulation of muscle specific factors of the regulatory program that controls myogenesis, such as myogenin, began to increase [23]. Cardiac Troponin T levels also began to increase around 12 h while a decrease in nestin levels was observed in agreement with earlier observations made on different cell lines induced to differentiate into myotubes [24,25]. Finally, desmin levels remained constant during the early period studied (not shown), since its accumulation is a late event during myogenesis [24].
Based on the observations reported above, we tested whether accumulation of P82,84 was regulated at the level of its mRNA. Total RNA was extracted from undifferentiated and stimulated C2C4 myoblasts at different times and subjected to Northern blot analyses. Membranes were sequentially probed with $^{32}$P-labeled exon 15 and various cDNA inserts. The results presented in Figure 6 (lower panels) representative of three independent time-course analyses, showed that muscle-specific exon 15 (81 nucleotides) hybridized to the two FXR1 transcripts of 3.2 and 2.4 kb [10,18]. In agreement with the results obtained at the protein level, these mRNA variants are present at low levels in non-differentiated myoblasts. Densitometric analysis showed a clear and significant increase ($3.0 \pm 0.5$) of both transcripts at 15 h after serum deprivation, then after their steady state levels continued to augment to reach a 5 fold increase by 24 h. The beginning of this increase coincided in time with that of myogenin and cardiac actin mRNAs, which began to accumulate at 12-15 h. In contrast, myf 5 mRNA levels decreased gradually as expected [26]. These results clearly indicate that accumulation of the FXR1 mRNA variants containing the muscle-specific exon 15 tightly correlates with the activation of muscle-specific genes.

**FXR1P82,84 are absent from polyribosomes in undifferentiated myoblasts**

Given the association of FXR1P with mRNPs present in polyribosomes [12], we asked whether all the different FXR1P isoforms would be found present in mRNP engaged in the translational machinery. Post-nuclear supernatants were prepared from non-induced myoblasts as well as from myotubes at day 3 after serum deprivation and analyzed by sedimentation velocity through sucrose density gradients. Immunoblot analyses of each collected fraction using the different antibodies to FXR1P showed that in extracts from non-induced cells, FXR1P70,74,78,80 co-fractionated with light polyribosomes, while in extracts prepared from myotubes, P70,74,78,80 and P82,84 were detected in heavier sedimenting structures (Figure 7). Further evidence that the FXR1P82,84 isoforms were associated with mRNP engaged in polyribosomes was obtained after treatment of these structures with EDTA that causes dissociation of ribosomes into their large and small subunits and the release of the associated mRNPs. After such a treatment, P82,84 were recovered as heterogeneous slower sedimenting structures with the majority peaking around 60-70 S (Figure 7). These results indicate that similarly to their closely related homologues FMRP and FXR2P, all FXR1P members are also associated with mRNPs within the translational machinery.

In repeated analyses using the highly specific antibodies #27-15 and #27-17, we were unable to detect P82,84 in polyribosomes and in mRNPs extracted from myoblasts (Figure 7). This was puzzling since these isoforms were constantly detected in total protein extracts (see Figures 5 and 6) and we hypothesized that P82,84 would have been retained in the 10 000 x g pellet during the preparation of the cytoplasmic extracts. Indeed, crude preparations of nuclear and cytoplasmic fractions from myoblasts showed that P82,84 were recovered associated with the nuclear fraction while no signals were detected in the cytoplasm (Figure 8). In contrast, we estimated that approximately 95% of P82,84 were present in the cytoplasmic fraction in myotubes, while the remaining 5% were observed associated with the nuclear fractions. Since the intensities observed in both nuclear preparations of myoblasts and myotubes were similar, these results indicate that equivalent amounts of FXR1P82,84 are present in nuclei regardless of the differentiation.
stage of the cells.

**Nuclear localization of FXR1P82,84 in undifferentiated myoblasts**

The results reported above clearly showed that the low levels of FXR1P82,84 isoforms present in myoblasts are not associated with polyribosomes and are recovered in the nuclear pellet after cell lysis. These observations prompted us to determine the *in situ* localization of P82,84 in differentiated and undifferentiated C2C4 cells. Immunofluorescent studies were performed using the different antibodies to FXR1P. In myoblasts, a clear cytoplasmic staining was observed for P70,74,78,80 and for P78,80 using mAb3FX and #830, respectively (Figure 9). Very faint signals were also observed at the level of nuclei, and were confirmed to be intranuclear by confocal microscopy (Figure 9 upper panels). Since P82,84 represent a very minor fraction of total FXR1P in myoblasts (see Figures 5 and 8) it was not possible to distinct these isoforms with mAb3FX or #830 by immunofluorescent reaction due to the strong cytoplasmic staining of the other FXR1P isoforms. However, when antibody #27-15 was used, a granular pattern of nucleoplastic distribution of P82,84 was observed as dot-like structures, which in some instances corresponded to DAPI stained dots (Figure 9). It should be noted that prolonged exposure times were required to capture the intranuclear images of P82,84. In cultures maintained in low serum for 3 days, typical fused myotubes were observed as elongated syncitia containing multiple nuclei and a strong cytoplasmic staining of all isoforms including P82,84 was observed in agreement with the results obtained at the level of polyribosomes analyses (see Figure 7).

**Discussion**

Fragile X Related 1 protein belongs to the FMR family of RNA binding proteins which are specifically associated with mRNPs engaged in actively translating ribosomes. All members of this family share the same protein structure and contain key domains that are conserved in RNA binding proteins [reviewed in 27] as well as NL and NE signals which allow the proteins to shuttle between the cytoplasm and the nucleus [8,28,29,30]. Indeed, accumulation of the FMR proteins in the nucleus has been observed experimentally with truncated variants of the proteins [28,30] as well as after overexpression experiments followed by treatment with Leptomycin B, an antibiotic that inhibits the nuclear export of NES-containing proteins [31,32]. Due to extensive alternative splicing of the FMRP primary transcript [33,34], it is believe that at least 20 different FMRP isoforms might exist. However, using the available antibodies, only 6 FMRP variants have been observed [35,36,37]. Similarly to FMR1, FXR1 primary transcript undergoes complex alternative splicing, however yielding in theory a much more modest number of protein isoforms. Recent studies [18] showed that 7 mRNA variants are detected, and our analyses in mouse organs revealed that unlike FMRP, the different FXR1P isoforms are tissue-specific. In general, P70,74,78,80 are widely expressed, albeit at different levels, and their respective ratio seem to be cell and tissue specific. In heart and skeletal muscle, these short and long protein isoforms are absent and are replaced by the P82,84 super long isoforms that are generated by a small peptide insert of 27 aa [12].

While FMRP is abundant in neurons, it is absent in muscle [12,35]. On the other hand, FXR1P82,84 specific to muscle has not been detected in neurons or in brain extracts [12 and this study]. This tissue specificity is not maintained in culture of undifferentiated myoblasts since both FMRP and P82,84 are detected in these cells [12]. In addition, P70,74,78,80 isoforms which are absent in muscle are clearly present in myoblasts. These observations suggest that the individual FMR members may be interchangeable in certain physiological conditions such as cell deadaptation in culture [38] or under cellular reprogramming during wound healing [35]. Using the model system of myoblast induced to differentiate into myotubes, we provide evidence that expression of the non-muscle to muscle-specific isoforms of FXR1P correlates with cellular differentiation. We observed that the levels of P82,84 and that of muscle mRNA variants begin to increase at an early time after stimulation concomitant with the expression of different markers of myogenesis. Accumulation of these super long isoforms is paralleled by the decrease of the short and long isoforms and finally at day 3 when approximately 80% of the cells underwent myotube differentiation, P82,84 accounted for the great majority of FXR1P. These results strongly suggest that the mechanisms by which FXR1P82,84 expression are controlled, reside at the level of splicing of the primary transcript. Further analyses are required to determine the factors associated with the expression of these muscle mRNA variants.

In undifferentiated myoblasts, P82,84 make exception in the FMR protein family since they are not associated with polysomal mRNPs and are sequestered in the nucleus. One possible explanation for this localization would have been that these isoforms contain, in addition to the canonical NLS found in all FMR protein members, a second nuclear localization signal. In fact, Tamanini et al. [39] recently reported that the 27 aa pocket insert contains a short arginine rich motif (QRRNRSRRR) identical to amino acids 35 to 44 present in a domain that
confers nucleolar localization to the HIV Rev protein [40]. Although a similar (PQRSTSRHRRGQ) peptide present in the 27 aa pocket, when coupled to a dye, has been shown to penetrate the cell and target the nucleolus [39], transient expression of all FXR1P isoforms, with or without the 27 aa pocket, localize exclusively to the cytoplasm [39 and our unpublished results]. Thus, it is not established that localization of FXRP82,84 is under the control of this peptide sequence. On the other hand, proteins that have been considered to be strictly nucleoplasmic, such as the hnRNPs [27] or the Rev proteins [41], have subsequently been found to shuttle between the nucleus and the cytoplasm [42,43,44,45]. In addition, hnRNPs have been shown to participate in the processing of pre-mRNAs and in the transport of mRNAs to the cytoplasm, and have even been suggested to play a role in translational regulation [46,47,48]. We propose that FXR1P82,84 might be sequestered in nucleoplasmic complexes in undifferentiated myoblasts and once cells are committed to differentiate, P82,84 are transferred to the cytoplasm with mRNPs carrying the newly processed mRNAs specific to the differentiated stage of myotubes.

According to our working hypothesis, a nuclear role, yet to be defined, for FXR1P82,84 in undifferentiated myoblasts, is conceivable.

Conclusions

Previous studies on the FMR proteins have shown that although the FXR1 protein is predominantly cytoplasmic, in rare occasions a nuclear localization has been observed in undifferentiated cells in several tissues of human foetuses and mouse embryo [15,49]. The model system of C2C4 myoblasts that can be manipulated in vitro to differentiate into myotubes provides strong evidence that specific isoforms of FXR1P are indeed sequestred in the nucleus in undifferentiated myoblasts. As a working hypothesis we propose that the pattern of nucleo-cytoplasmic partitioning of FXR1P isoforms is under the control of factors regulating cell differentiation. By extension, we also speculate that isoforms of FMRP, that for the moment have escaped detection due to the very restricted number of available antibodies, might play a nuclear role in mRNA maturation at specific stages of neuronal differentiation and plasticity. In conclusion, the model system described here should be considered as a powerful tool for ongoing attempts to unravel structure-function relationships of the different FMR family members since the potential role(s) of FXR1P and FXR2P as a compensatory factor(s) in Fragile X Mental Retardation is still elusive.

Figure 6
Accumulation of FXR1P82,84 is an early event and coincides with expression of different myogenic markers. Protein (40 µg) and RNA (5 µg) were prepared at the indicated times and subjected to immunoblot (Western) and Northern analyses, respectively. Exposure times for Western analyses were between 15 and 30 sec. Northern blots were exposed for 36 h while the 81 bp insert required prolonged exposure up to 72 h due to the short probe used. hps: hours post-stimulation after serum deprivation.
Material and Methods

Cell culture

The mouse myogenic cell line C2C4, a subclone of the mouse skeletal muscle cell line C2, [22] was obtained from Chistian Pinset, Institut Pasteur, Paris, France. Cultures were routinely maintained at low cell density in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal calf serum (FCS) plus antibiotics (100 units/ml penicillin, 50 µg/ml streptomycin). Cultures were usually initiated with $3 \times 10^4$ cells in 100-mm diameter petri dishes. After 4 days of culture, differentiation was induced by replacing the medium with DMEM containing 0.2% FCS.

Protein studies

Two synthetic polypeptides of 15 (DDSEKKPQR-RNRSRR) and 17 (NRSRRRRFRGQAEDRQP) amino acids present in the muscle peptide insert of 27 aa [12] were synthesized on a branched lysine residue (MAP carrier core technique by Research Genetic, Huntsville, Alabama) and used for immunization of rabbits using standard protocols and two polyclonal sera #27-15 and #27-17 were obtained. The monoclonal antibody 3FX and the polyclonal #830 anti-serum that detect different epitopes, have been described previously [12].

Total proteins from cell cultures and from various mouse tissues were prepared as described [37]. Immunodetection analyses were performed using the following antibodies: mAb3FX and #830 [12], #27-15 and #27-17 (this study) for FXR1P. Hybridoma supernatants for cardiac troponin T (CT3; developed by JJ-C Lin), myogenin (F5D; WE Wright), nestin (Rat-401; S Hockfield), and desmin (D3; DA Fischman) were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242 (http://www.uiowa.edu/~dshbwww/). Immunoreaction was detected using horse radish perox-
idase-conjugated secondary antibodies followed by the ECL (Amersham Pharmacia Biotech) reaction and exposure to Kodak Biomax MR films. High resolution two-dimension gel electrophoresis was conducted essentially as described [50] with the following modifications. The first IEF dimension contained 9 M urea, 2% Ampholynes pH 3.5-10 (Amersham Pharmacia Biotech AB) and 2% of CHAPS (Sigma, St Louis, MO) instead of 2% NP-40, and electrophoresis was conducted for 14 000 V/h under a constant current of 300 V. The second SDS-PAGE dimension consisted of a 7.5% acrylamide gel. Distribution of the different FXR1P isoforms in nuclear, cytoplasmic and polysome fractions were conducted as described previously [10] in the presence of Complete™, Mini (Roche Diagnostics) protease inhibitors cocktail.

RNA studies

Total RNA was prepared using the Trizol reagent (GIBCO). Northern blot analyses were performed as described [51]. RNA was estimated by optical density at 260 nm and corrected for even loading (5 µg) after dot blot hybridization with a 32P-labeled 18S rRNA probe followed by radioactivity determination by liquid scintillation counting. cDNA inserts for myogenin, myf5 [52], and cardiac actin [53] were 32P-labeled by random priming. To obtain a specific probe to FXR1 exon 15, the 81 bp was cloned in pCR®II plasmid and amplified by PCR using as primers CAGGAAACAGCTATGACC (forward) and ATACGACTCACTATAGGG (reverse). The short 297 bp fragment obtained was labeled by random priming. Densitometric analyses were performed on autoradiograms using the NIH Image 1.62f program.

Immunofluorescence microscopy and immunohistochemistry

Immunoreactions on cells grown on glass coverslips and on sections from mouse organs were performed as previously described [12]. Fluorescent and light microscopy were viewed with a Nikon TE300 microscope connected to a CoolSnap camera (RS Photometrics) using a 100 x oil immersion objective. Confocal images were obtained with a Zeiss LSM-310 microscope and images were colored using the Adobe PhotoShop program.

Acknowledgments

We thank Sylvie Giroux and Michel Vincent for helpful discussions, Michael Rudnicky, and Christian Pinset for cDNA probes and cell lines, Sandra Tremblay for technical assistance and Yves Labelle for critical reading of the manuscript. This work was supported by the Natural Sciences and Engineering Research Council of Canada. M.D. was supported by a studentship from le Fonds pour la Formation des Chercheurs et l'Aide à la Recherche du Québec.

References

1. Imbert G, Feng Y, Nelson DL, Warren ST, Mandel JL: FMR1 and mutations in fragile X syndrome: Molecular biology, biochemistry, and genetics. In Genetic instabilities and hereditary neurological diseases. Edited by Wells RD and Warren ST. New York: Academic Press, 1996, 27-53
2. Khandjian EW: Biology of the fragile X mental retardation protein, an RNA-binding protein. Biochem Cell Biol 1999, 77:331-342
3. Coy JF, Sedlacek Z, Bachner D, Hameister H, Joos S, Lichter P, Delius H, Pousta A: Highly conserved 3' UTR and expression pattern of FXR1 points to a divergent gene regulation of FXR1 and FMR1. Hum Mol Genet 1995, 4:2209-2218
4. Siomi MC, Siomi H, Sauer WH, Srinivasan S, Nussbaum RL, Dreyfuss G: FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J 1995, 14:2401-2408

Figure 9
Intracellular localization of the short, long and super long FXR1P isoforms by indirect immunofluorescence in myoblasts and myotubes as detected with the different antibodies to FXR1P. Confocal (upper panels) and light (lower panels) microscopy analyses after reaction with the different anti-FXR1P antibodies. Nuclei were counterstained with DAPI. Scale bars: = 5 µm.
The fragile X mental retardation protein interacts with novel homologs FXR1 and FXR2. **EMBO J** 1995, 14:3538-3566.

Ashley CT Jr, Wilkinson KD, Reines D, Warren ST: **FMRI protein: Conserved RNP family domains and selective RNA binding.** Science 1993, 262:563-566.

Soni H, Soni MC, Nussbaum RL, Dreyfuss G: **The protein product of the fragile X gene, FMRI, has characteristics of an RNA-binding protein.** Cell 1993, 74:291-298.

Eberhart DE, Malter HE, Feng Y, Warren ST: **The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals.** Hum Mol Genet 1996, 5:1083-1091.

Khandjian EW, Corbin F, W woerly S, Rousseau F: **The fragile X mental retardation protein is associated with ribosomes.** Nature Genet 1996, 1:291-93.

Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T, Hoo-geveen AT: **Oligomerization properties of fragile-X mental retardation protein is cytoplasmic, most abundant in neurons and appears within the nuclear envelope.** Hum Mol Genet 1996, 5:1083-1091.

Cemen S, Brown V, Warren ST: **The fragile X syndrome protein FMR1 and the FXR2 proteins mediate their binding to 60 S ribosomal subunits and the interactions among them.** Mol Cell Biol 1996, 16:325-332.

Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST: **Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex.** Mol Cell Biol 1999, 19:7925-7932.

Tamarini F, Willens R, van Unen L, Bontekoe C, Galjaard H, Oos-tra BA, Hoevegeen AT: **Differential expression of FMRI, FXR1 and FXR2 proteins in human brain and testis.** Hum Mol Genet 1997, 6:1315-1322.

Bakker CE, de Vries B, van der Meulen JM, Abbas A, Malter HE, Tamarini F, Willens R, van Unen L, Bontekoe C, Galjaard H, Oostra BA, Hoevegeen AT, Willemsen R: **Characterization and localization of the FMR-1 gene product and the biogenesis of mRNA.** Hum Mol Genet 1997, 6:1083-1091.

Lindon C, Montarras D, Pinset C: **Cell cycle-regulated expression of the muscle determination factor Myf5 in proliferating myo- lastocytes.** J Cell Biol 1998, 140:111-118.

Dreyfuss G, Matunis MJ, Pilho-Roma S, Burd CG: **hnRNPI proteins and the biogenesis of mRNA.** Annu Rev Biochem 1993, 62:289-321.

Sitter A, Devys D, Weber C, Mandel JL: **Alternative splicing of exon 14 determines nuclear or cytoplasmic localization of fragile X mental retardation protein.** Hum Mol Genet 1996, 5:95-102.

Fridell RA, Benson RE, Hua J, Bogerd HP, Cullen BR: **A nuclear role for the fragile X mental retardation protein.** EMBO J 1996, 15:5408-5414.

Barnoud B, Sitter A, Shen Y, Mandel JL: **Analysis of domains affecting intracellular localization of the FMRP protein.** Neurobiol Disease 1997, 3:329-336.

Tamura F, Bontekoe C, Bakker E, van Unen L, Anar B, Willemsen R, Yoshida M, Galjaard H, Oostra BA, Hoevegeen AT: **Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations.** Nature Genet 1999, 2:399-404.

Wolff B, Sangler J-J, Wang Y: **Leptomycin B is an inhibitor of nuclear export: inhibition of nuclear-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent RNA.** Chemistry and Biology 1997, 4:139-147.

Ashley CT, Scuitlffe JS, Kunst B, Leiner HA, Eichler EE, Nelson DL, Warren ST: **Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat.** Nature Genet 1993, 4:244-251.

Verkerk AJMH, de Graaff E, De Boulle K, Eichler EE, Koonecki D, Reynolds E, Manca A, Poustka A, Willems P, Nelson DL et al: **Alternative splicing in the fragile X gene FMR1.** Hum Mol Genet 1993, 2:399-404.

Deys D, Luzh Y, Rouyer N, Belloq J-P, Mandel JL: **The FMR1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.** Nature Genet 1993, 4:335-340.

Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verk-erk AJMH, Galjaard H, Reuser AJJ, Hoevegeen AT, Oostra BA: **Characterization and localization of the FMR1 gene product associated with fragile X syndrome.** Nature Genet 1999, 26:722-724.

Khandjian EW, Fortin A, Thibodeau A, Tremblay S, Côté F, Devys D, Khandjian EW, Corbin F, Sitter A, Shen Y, Mandel JL: **A heterogeneous set of FMR1 proteins is widely distributed in mouse tissue and is modulated in cell culture.** Hum Mol Genet 1995, 4:783-789.

Freshney IR: **Culture of Animal Cells; a Manual of Basic Technique.** New York, Alan R Liss, Inc. 1987.

Tamarini F, Krickhalk PL, Schonkenar J, van Unen L, Bontekoe C, Bakker CE, de Graaff E, Nelson DL, Galjaard H, Oostra BA, Hoevegeen AT: **Functional mapping of the human immunodeficiency virus type 1 (HIV-1) Rev RNA and Rev-dependent RNA.** Cell 1997, 88:475-483.

Bohnlein B, Berger J, Hauber J: **Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: New insights into the domain structure of Rev and Rex.** J Virol 65:7051-7055.

Frankel AD, Young JAT: **HIV-1: Fifteen proteins and an RNA.** Annu Rev Biochem 1998, 67:1-25.

Piñol-Roma S, Dreyfuss G: **Shuttling of pre-mRNA binding pro- teins between nucleus and cytoplasm.** Nature 1992, 355:730-732.

Kalland KH, Szilvay AM, Broksstad KA, Saetrevik W, Haukenes G: **The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and the nuclear compartments.** Mol Cell Biol 1994, 14:7436-7444.

Fischer U, Huber J, Boelens WC, Mattaj IW, Lührmann R: **The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.** Cell 1995, 82:475-483.

Michaël WM, Choi M, Dreyfuss G: **A nuclear export signal in hnt-RNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway.** Cell 1995, 83:415-422.

Gamarnik AV, Andino R: **Two functional nucleolar complexes formed by KH domain containing proteins with the 5' noncoding region of poliovirus RNA.** RNA 1997, 3:882-892.

Ostereck DH, Ostereck-Lederer A, Wilm M, Thiele BJ, Mann M, Hentze MW: **mRNA silencing in erythroid differentiation: hn-
RNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end. Cell 1997, 89:597-606

48. Ostareck-Lederer A, Ostareck DH, Hentze MW: Cytoplasmic regulatory functions of the KH-domain proteins hnRNP K and E1/E2. Trends Biochem Sci 1998, 23:409-411

49. de Diego Otero Y, Bakker CE, Raghoe P, Severijnen WFM L-A, Hoogeveen A, Oostra BA, Willemsen R: Immunocytochemical characterization of FMRP, FXR1P and FXR2P during embryonic development in the mouse. Gene Funct Dis 2000, 1:28-37

50. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250:4007-4021

51. Khandjian EW: UV crosslinking of RNA to nylon membrane enhances hybridization signals. Molec Biol Reports 1986, 11:107-115

52. Montarras D, Chelly J, Bober E, Arnold H, Ott MO, Gros F, Pinset C: Developmental patterns in the expression of Myf5, MyoD, myogenin, and MRF4 during myogenesis. New Biol 1991, 3:592-600

53. Minty AJ, Caravatti M, Robert B, Cohen A, Daubas P, Weydert A, Gros F, Buckingham ME: Mouse actin mRNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse α-actin mRNA. J Biol Chem 1981, 256:1008-1014